The UK’s medicines regulator has authorised a world-first gene therapy as a potential cure for two inherited blood disorders.
The treatment, Casgevy, for sickle cell disease and beta thalassemia, is the first to be licensed using the gene-editing tool known as Crispr, for which its inventors were awarded the Nobel prize in 2020.
